Biocardia Financial Statements From 2010 to 2025

BCDA Stock  USD 1.23  0.04  3.15%   
Biocardia's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biocardia's valuation are provided below:
Gross Profit
-5.2 M
Market Capitalization
13.5 M
Enterprise Value Revenue
3.1 K
Earnings Share
(1.42)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental signals for Biocardia, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Biocardia prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. As of December 30, 2025, Market Cap is expected to decline to about 15.4 M. In addition to that, Enterprise Value is expected to decline to about 15.6 M

Biocardia Total Revenue

55,100

Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia's main balance sheet or income statement drivers, such as Depreciation And Amortization of 63.6 K, Interest Expense of 6.6 K or Selling General Administrative of 3.3 M, as well as many indicators such as Price To Sales Ratio of 97.98, Dividend Yield of 0.03 or PTB Ratio of 7.5. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules.
  
Build AI portfolio with Biocardia Stock
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.

Biocardia Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.5 M3.7 M11.1 M
Pretty Stable
Total Current Liabilities1.5 M2.3 M1.9 M
Slightly volatile
Property Plant And Equipment Net668.1 K931 K612.3 K
Slightly volatile
Accounts Payable427.5 K385 K494.1 K
Slightly volatile
Cash2.3 M2.4 M9.9 M
Slightly volatile
Non Current Assets Total1.4 M1.1 M741 K
Slightly volatile
Non Currrent Assets Other235.3 K196.7 K100.4 K
Slightly volatile
Cash And Short Term Investments2.3 M2.4 M9.9 M
Slightly volatile
Common Stock Total Equity17.5 K18.4 K112.4 K
Slightly volatile
Common Stock Shares Outstanding2.9 M2.7 M940.3 K
Slightly volatile
Liabilities And Stockholders Equity3.5 M3.7 M11.1 M
Pretty Stable
Non Current Liabilities Total630 K566 K623.9 K
Slightly volatile
Other Current Assets435.9 K251 K357.9 K
Pretty Stable
Total Liabilities1.7 M2.9 M2.3 M
Slightly volatile
Property Plant And Equipment Gross862.7 K1.7 M732.7 K
Slightly volatile
Total Current Assets2.5 M2.6 M10.4 M
Slightly volatile
Common Stock4.8 KK110.2 K
Slightly volatile
Short Term Investments324.8 K483.5 K512 K
Pretty Stable
Good Will986.4 K1.1 M1.2 M
Slightly volatile
Intangible Assets3.7 M3.9 M4.3 M
Slightly volatile
Short and Long Term Debt Total1.9 M951 K3.1 M
Slightly volatile
Short Term Debt365.8 K385 K2.5 M
Slightly volatile
Capital Surpluse163.3 M155.5 M84.1 M
Slightly volatile
Other Liabilities834.4 K794.6 K344.3 K
Slightly volatile
Property Plant Equipment2.1 MM788.7 K
Slightly volatile
Preferred Stock Total Equity36.8 M41.4 M45.2 M
Slightly volatile
Deferred Long Term Liabilities75.3 K93.2 K70.5 K
Slightly volatile
Capital Stock4.8 KK30 K
Slightly volatile
Capital Lease Obligations1.4 M951 K1.2 M
Pretty Stable

Biocardia Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization63.6 K67 K127.1 K
Pretty Stable
Interest Expense6.6 K6.9 K136.2 K
Very volatile
Selling General Administrative3.3 M3.7 M3.1 M
Slightly volatile
Total Revenue55.1 K58 K620.4 K
Pretty Stable
Other Operating Expenses6.5 M8.1 M7.8 M
Slightly volatile
Cost Of Revenue4.6 M4.4 M2.9 M
Slightly volatile
Total Operating Expenses5.6 M3.7 M6.7 M
Slightly volatile
Research Development5.4 M4.4 MM
Slightly volatile
Interest Income7.7 K8.1 K212.6 K
Very volatile
Selling And Marketing Expenses2.1 M2.4 M2.6 M
Slightly volatile
Reconciled Depreciation63.8 K67 K78 K
Pretty Stable

Biocardia Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash FlowM1.1 M9.1 M
Very volatile
Depreciation63.6 K67 K74 K
Very volatile
Dividends Paid378 K397.9 K337.4 K
Slightly volatile
End Period Cash Flow2.3 M2.4 M9.9 M
Slightly volatile
Stock Based Compensation1.1 M741 K1.2 M
Slightly volatile
Issuance Of Capital Stock7.7 M10.6 M6.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio97.98103225
Pretty Stable
Dividend Yield0.030.03380.0368
Slightly volatile
Days Sales Outstanding41.2243.39313
Pretty Stable
Average Payables4.4 K4.6 K17.5 K
Slightly volatile
Stock Based Compensation To Revenue13.4112.77594.4438
Slightly volatile
Capex To Depreciation0.08510.08961.0143
Slightly volatile
Payables Turnover1.061.116938.3289
Slightly volatile
Sales General And Administrative To Revenue12.578.9612.3231
Slightly volatile
Research And Ddevelopement To Revenue79.4275.637920.5636
Slightly volatile
Capex To Revenue0.09830.10340.8448
Slightly volatile
Cash Per Share0.820.8641409
Slightly volatile
Days Payables Outstanding3103274.6 K
Pretty Stable
Intangibles To Total Assets0.50.410.382
Very volatile
Current Ratio1.071.1297293
Slightly volatile
Receivables Turnover7.678.716.0546
Very volatile
Capex Per Share0.00210.00223.4616
Slightly volatile
Average Receivables179.1 K188.6 K182.9 K
Slightly volatile
Revenue Per Share0.02010.021140.1701
Slightly volatile
Interest Debt Per Share0.330.3466157
Slightly volatile
Debt To Assets0.280.25540.2874
Slightly volatile
Graham Number1.7 K9971.4 K
Slightly volatile
Days Of Payables Outstanding3103274.6 K
Pretty Stable
Ebt Per Ebit0.820.99311.0596
Pretty Stable
Effective Tax Rate0.0090.00950.0094
Slightly volatile
Quick Ratio1.071.1297281
Slightly volatile
Cash Ratio0.971.0215120
Slightly volatile
Days Of Sales Outstanding41.2243.39313
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.00070.9141
Slightly volatile
Fixed Asset Turnover0.05920.06233.1795
Slightly volatile
Debt Ratio0.280.25540.2874
Slightly volatile
Price Sales Ratio97.98103225
Pretty Stable
Asset Turnover0.01480.01560.2561
Slightly volatile

Biocardia Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.4 M16.2 M184 M
Slightly volatile

Biocardia Fundamental Market Drivers

Biocardia Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biocardia Financial Statements

Biocardia stakeholders use historical fundamental indicators, such as Biocardia's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biocardia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biocardia's assets and liabilities are reflected in the revenues and expenses on Biocardia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue532 K558.6 K
Total Revenue58 K55.1 K
Cost Of Revenue4.4 M4.6 M
Stock Based Compensation To Revenue 12.78  13.41 
Sales General And Administrative To Revenue 8.96  12.57 
Research And Ddevelopement To Revenue 75.64  79.42 
Capex To Revenue 0.10  0.10 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(137.95)(131.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.42)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.86)
Return On Equity
(3.17)
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.